The most common side effects were nausea, constipation and diarrhea
As the science continues to evolve, were seeing that these benefits may extend to people who dont necessarily need to lose weight, and thats opened up an interesting conversation about why people are microdosing GLP-1 medications
doi: 10.3389/fpsyg.2019.00634, 138 SticeE.SpoorS.BohonC.SmallD
The ESSENCE trial showed 30-40% reductions in liver enzymes
S4: Strong IP position
Real-World Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss and Glycemic Control: A Retrospective Cohort Study Neil Jethani, PhD^ and Shivaani Prakash, MSc, PhD^ ^ Dandelion Health, Syosset, NY Introduction The high prevalence of both type 2 diabetes mellitus (T2DM) and obesity in the United States has wide-ranging implications for population health, clinical care, and health care costs